HLA-C and melanoma: A study performed WES on 294 microsatellite stable tumors (including 151 melanomas) and concluded that TMB did not have sufficient predictive power to distinguish tumor response from PD.36 Prediction incorporating multiple variables, such as TMB, MHC haplotype and T-cell receptor repertoire, might be needed.35 On the other hand, MM was demonstrated to be a low-TMB tumor,9 which may explain the lack of clinical efficacy correlation with TMB in this study.